RecruitingPhase 2Drug trialEfficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface DiseaseIn this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.